Skip to search formSkip to main contentSkip to account menu

Nesvacumab

Known as: Anti-ANG2 MOAB REGN910, REGN910 
A fully human monoclonal antibody directed against angiopoietin 2 (ANG2) with potential antiangiogenic and antineoplastic activities. Nesvacumab… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

SAR307746
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Aflibercept in combination with nesvacumab (anti-Ang2) induces vascular remodeling in a rabbit model of pathological neovascularization.
2016
2016
Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer
Phase III clinical trials evaluating bevacizumab (an antibody to the angiogenic ligand, VEGF-A) in breast cancer have found… 
2014
2014
Abstract 4492: Blockade of angiopoietin-2 or Tie2 is equally effective at inhibiting tumor growth and reducing tumor vessel density in most human tumor xenograft models
Angiopoietin-1 (Ang1) and -2 (Ang2) regulate angiogenesis via the endothelial cell-specific receptor tyrosine kinase Tie2… 
2014
2014
Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hepatocellular carcinoma (HCC) cohort.
2540 Background: Nesvacumab (N) is an Ang2 selective, human MAb that potently blocks signaling through the Tie2 receptor… 
2014
2014
A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies.
2522 Background: Nesvacumab (N) is a selective, human Ang-2 MAb, that potently blocks Ang2 signaling through the Tie2 receptor… 
Review
2014
Review
2014
Critical role of angiopoietin pathway in Ischemia-reperfusion injury In cardiac transplantation
................................................................................. 12 INTRODUCTION… 
2013
2013
A phase I first-in-human study of REGN910 (SAR307746), a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb), in patients with advanced solid tumor malignancies.
2517 Background: REGN910 is a selective, fully human Ang2 MAb that potently blocks signaling through the Tie2 receptor regulating… 
2013
2013
A phase Ib study of combined angiogenesis blockade with REGN910 (SAR307746), a selective monoclonal antibody (MAb) against angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid…
TPS2618 Background: REGN910 is a selective, fully human Angiopoietin-2 (ANG-2) MAb, which potently blocks signaling through the… 
2011
2011
A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies.
TPS159 Background: Angiopoietin-2 (Ang2) is a secreted growth factor that functions as a critical regulator of angiogenesis… 
2011
2011
Abstract 3290: REGN910, a fully-human, Ang2-specific monoclonal antibody, inhibits tumor growth as a monotherapy and dramatically potentiates the effects of VEGF Trap (aflibercept)
Inhibition of tumor angiogenesis via blockade of vascular endothelial growth factor (VEGF) has proven to be beneficial in several… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)